


California Department of Public Health Immunization Updates for Providers

Friday, November 17, 2023

9:00AM – 10:30AM

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be
dropped into, “Chat”



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#)



To be added to the CDPH email messaging listserv for providers, please email your request to billiedawn.greenblatt@cdph.ca.gov

If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov

Agenda: Friday, November 17, 2023

| No. | Item | Speaker(s) | Time (AM) |
|------------|--|--|--------------|
| 1 | Welcome and Announcements | Leslie Amani (CDPH) | 9:00 – 9:05 |
| 2 | Vaccine Administration Data | Sarah Stich (CDPH) | 9:05 – 9:10 |
| 3 | Clinical Update: Mpox | Tarek Salih, MD (CDPH) | 9:10 – 9:20 |
| 4 | Pharmacy | Edward Salaguinto, PharmD, RPh (CDPH) | 9:20 – 9:25 |
| 5 | Vaccine Management | Josh Pocus (My Turn) and Claudia Aguiluz (myCAvax) | 9:25 – 9:35 |
| 6 | Vaccines for Children (VFC) Updates | Claudia Aguiluz (CDPH) | 9:35 – 9:45 |
| 7 | COVID-19 Vaccines and Low-Dead Volume Syringes | Kelley Leung, RN (CDPH) | 9:45 – 9:50 |
| 8 | Resources and Q&A | Leslie Amani (CDPH) | 9:50 – 10:30 |
| Thank you! | | | |

Announcements

Leslie Amani, CDPH



Holidays and Webinar Cancellations

Thursday, November 23: **Happy Thanksgiving!** 

Friday, November 24: There will be **no** Friday provider webinar the day after Thanksgiving.

Please note that the Provider Call Center will be closed on these same dates.



Vaccines for Children (VFC) Afternoon TEAch Webinar

**Save the date for our next VFC TEAch Webinar:
“What’s New with Winter Respiratory Viruses?”**



When: Thursday, December 7, 2023, at 12pm – 1pm (PT)

Topics:

- Clinical recommendations on Maternal RSV vaccine
- Vaccine storage and handling updates
- VFC recertification process: recommendations and updates

Description: This Afternoon TEAch webinar will cover what's new with Winter Respiratory Viruses, specifically as related to the Vaccines for Children (VFC) program.

When: Thursday, December 7, 2023

Time: 12PM – 1PM, PT

[Register here](#)



Upcoming Crucial Conversations Webinar

Topic: Having Respectful and Caring Immunization Conversations with Older Adults in Black, Indigenous, People of Color (BIPOC) Communities

Description: Discover the current landscape of respiratory viruses for older adults and learn key messages for addressing common vaccine concerns among older adults in BIPOC communities.

Speaker: Asha Shajahan, M.D., MHSA

When: Wednesday, December 13, 2023

Time: 12PM - 1PM, PT

Please register [here](#)

Crucial Conversations

Upcoming Webinar:
Having Respectful and Caring Immunization Conversations with Older Adults in BIPOC Communities

Please join
Asha Shajahan, M.D., MHSA

Find out more about the current landscape of respiratory viruses for older adults, and learn key messages for addressing common vaccine concerns among older adults in BIPOC communities.

**Wednesday, December 13th, 2023
12:00PM - 1:00PM PT**

Register here!

#THIS IS OUR SHOT **#VACU NATE YA**

California Department of Public Health

American Academy of Pediatrics (AAP)



Webinar: Nirsevimab Supply and Prioritization Updates

November 10, 2023

[Watch Here](#)



Information for Parents on RSV In Availability


November 2, 2023

[HealthyChildren.org](#)

Reflections on COVID-19: Living and Learning in a Pandemic

Nirsevimab Supply and Prioritization Updates Webinar November 8, 2023

Healthy Children: RSV



Standing Orders: Respiratory Syncytial Virus (RSV) Immunizations

- Standing Orders for Nirsevimab
- Standing Orders for Administering RSV Vaccine During Pregnancy
- Standing Orders Templates Main Page

STANDING ORDERS FOR Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy

Purpose

To reduce morbidity and mortality from severe lower respiratory tract disease in pregnant individuals who meet the criteria established by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices.

Notes:

Two RSV vaccines (Abrysvo by Pfizer and Arexvy by GSK) are approved for use in a shared clinical decision-making involving considerations of patient health condition, clinical judgment and discussion required, there is no standing order template from Abrysvo is approved for use during pregnancy. For this reason, this template specifies Nirsevimab (a preventive antibody) is recommended for infants whose mothers do during pregnancy. The standing order template for nirsevimab is available at www.immunize.org.

Policy

Where allowed by state law, standing orders enable eligible nurses, pharmacists to assess the need for vaccination and to vaccinate pregnant individuals.

Procedure

1 Assessment:

Note: One dose of Abrysvo is licensed and routinely recommended by the CDC for a single dose of Abrysvo (must meet all of the following criteria):

- **Time of year:** September 1 through January 31 in most of the contiguous United States. These jurisdictions may include Alaska, southern Florida, Guam, Pacific Islands, and the U.S. Virgin Islands.
- **Gestational age:** between 32 weeks and 0 days through 36 weeks and 0 days.
- **Vaccination history:** No history of a previous dose of any RSV vaccine.
- **Maternal preference:** Either maternal Abrysvo vaccination or nirsevimab the infant is recommended. Both Abrysvo and nirsevimab are not mutually exclusive options, the pregnant person may choose maternal vaccination or infant nirsevimab.

2 Screen for Contraindications and Precautions

Contraindications

Contraindications: Do not give Abrysvo to a recipient who has experienced an allergic reaction to any of its components. For information on vaccine components, refer to www.immunize.org/fda, or go to www.cdc.gov/vaccines/pubs/pinkbook/table-2.pdf.

Precautions

Moderate or severe acute illness with or without fever.



FOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.org

STANDING ORDERS FOR Administering Nirsevimab RSV Preventive Antibody to Infants (2023–24 Season Only)

Purpose

To reduce morbidity and mortality from respiratory syncytial virus (RSV) by immunizing all infants who meet the criteria established by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) with a long-acting monoclonal antibody against RSV.

2023-24 Season Note: Due to strong early demand and limited supply of nirsevimab (Beyfortus, Sanofi), particularly 100-mg manufacturer-filled syringes (MFS), on October 24, 2023, CDC issued a Health Advisory with revised recommendations for use of nirsevimab during the 2023-24 season (see CDC Health Alert at <https://emergency.cdc.gov/han/2023/han00499.asp>). ACIP recommendations for infants weighing less than 5 kg are unchanged. This template follows CDC's limited nirsevimab recommendations for infants weighing 5 kg or more for the 2023-24 season. A routine template will be posted once restricted use is no longer recommended by CDC. Interim CDC recommendations are subject to change as new information becomes available.

RSV Vaccine Note: Between September 1 and January 31 each season, prevention of severe RSV disease in infants is recommended through administration of RSVpreF vaccine (Abrysvo, Pfizer) to the pregnant person between gestational week 32 and week 36 and 6 days, as an alternative to nirsevimab. If conditions (e.g., product availability) allow for the option of maternal vaccination or nirsevimab, the pregnant person may choose the preferred option. The standing order template for maternal vaccination with Abrysvo is available at www.immunize.org/p3096.pdf.

Policy

Where allowed by state law, standing orders enable eligible nurses and other healthcare professionals to assess the need for administration of a long-acting monoclonal antibody product to infants and young children who meet the criteria below.

Procedure

1 Assess infants in need of immunization against RSV disease in their first or second RSV season according to the following criteria:

1a. Routine dose for infants younger than 8 months and 0 days (must meet all criteria):

Timing: Generally, October 1 through March 31, unless use of nirsevimab outside of this time is currently recommended by regional experts or health authorities in response to local RSV activity. This seasonality is less likely outside the continental United States.

Infant immunization history: No history of nirsevimab; no history of palivizumab in the past 30 days.

No history of effective maternal RSVpreF vaccination for one of the following reasons:

- RSVpreF vaccine was not administered, or
- RSVpreF administration history is unknown, or
- RSVpreF administration occurred less than 14 days before delivery, or
- RSVpreF administration occurred 14 or more days before delivery, but protection may be inadequate for one of the following reasons (evaluation may require referral):
 - Mother is immunocompromised or living with HIV, or
 - Infant has undergone cardiopulmonary bypass or extracorporeal membrane oxygenation, or
 - Infant has hemodynamically significant congenital heart disease, or
 - Infant has had an intensive care admission requiring oxygen at hospital discharge.

CONTINUED ON THE NEXT PAGE ►



FOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.org

www.immunize.org/catg.d/p3097.pdf
Item #P3097 (11/6/2023)



Scan for PDF

COVID-19 Vaccine Fact Sheets

Topics include:

- Links to product info from manufacturers, FDA and CDC
- Schedule & intervals
- Packaging
- Dosage
- Shipping conditions
- Storage requirements
- Use-by limits
- Expiration dates (QR code, expiry checker)
- Vaccine Information Statements (VISs), or equivalent fact sheet
- Billing codes (private & public patients)

COVID-19 Vaccine Infant/Toddler (6M-4Y), 2023-2024 Formula

Vaccine Fact Sheet

| |
|------------------------------|
| Topic |
| Manufacturer |
| Product Info |
| Protects Against |
| Approved Ages |
| Routine Schedule & Intervals |
| Administration |
| Packaging |
| Dosage |
| Shipping |

California Department of

COVID-19 Vaccine Pediatric (5-11Y), 2023-2024 Formula

Vaccine Fact Sheet

Topic

Manufacturer

Product Info

Protects Against

Approved Ages

Routine Schedule & Intervals

Administration

Packaging

Dosage

Shipping

California Department of

COVID-19 Vaccine Adolescent/Adult (12Y+), 2023-2024 Formula

Vaccine Fact Sheet

| Topic | Comirnaty | Spikevax | Novavax COVID-19 Vaccine |
|------------------------------|---|---|---|
| Manufacturer | Pfizer-BioNTech | Moderna | Novavax |
| Product Info | Prescribing Info Pfizer at a Glance | Prescribing Info Moderna at a Glance | Prescribing Info Novavax at a Glance |
| Protects Against | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| Approved Ages | 12 years + (see age transition guidance) | 12 years + (see age transition guidance) | 12 years + |
| Routine Schedule & Intervals | <p>Individuals 12 years and older:</p> <ul style="list-style-type: none"> • Unvaccinated: 1 dose • Previously vaccinated with any COVID-19 vaccine: 1 dose at least 2 months after the last dose of COVID-19 vaccine • Immunocompromised: See CDC guidance | <p>Individuals 12 years and older:</p> <ul style="list-style-type: none"> • Unvaccinated: 1 dose • Previously vaccinated with any COVID-19 vaccine: 1 dose at least 2 months after the last dose of COVID-19 vaccine • Immunocompromised: See CDC guidance | <p>Individuals 12 years and older:</p> <ul style="list-style-type: none"> • Unvaccinated: 2 doses at least 3 weeks apart • Previously vaccinated with any COVID-19 vaccine: 1 dose at least 2 months after the last dose of COVID-19 vaccine • Immunocompromised: See CDC guidance |
| Administration | Intramuscular (IM) injection | Intramuscular (IM) injection | Intramuscular (IM) injection |
| Packaging | Single-dose vials – 10 vials per box | Single-dose vial – 10 vials per box (pre-filled syringes available for private purchase) | 5-dose vials – 2 vials per box (10 doses per box) |
| Dosage | 30 micrograms/dose (0.3 mL) | 50 micrograms/dose (0.5 mL) | 5 micrograms/dose (0.5 mL) |

California Department of Public Health, Immunization Branch

IMM-1493 (11/23)

Novavax COVID-19 Vaccine Resources

- [Novavax at a Glance](#) (CDC, 10/31/23)
- [Storage & BUD Tracking Labels](#) (CDC, 10/18/23)
- [Standing Orders](#) (CDC, 10/31/23)
- [Expiry Checker](#) (Novavax)
- [Temperature Excursion Checker](#) (Novavax)
- [CDC Resources by Product](#)

[COVID-19 Vaccine Product Training](#)


| Novavax Vaccines | Location Coordinator | Vaccinator | Provider |
|---|----------------------|------------|----------|
| • Novavax at a Glance (PDF) | ✓ | ✓ | ✓ |

Required for providers and staff administering Novavax for the first time

Moderna COVID-19 Vaccine 6M – 11Y Step-by-Step Video

[Moderna Training Video](#) provides a step-by-step guide for accurately drawing and administering pediatric COVID-19 vaccine

- Moderna COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 11 years is supplied in single-dose vials (SDVs)
- A single dose for this age group is 0.25 mL
- SDVs contain notably more than 0.25 mL of vaccine
- Discard the vial and excess volume after extracting a single dose



See [COVID-19 Vaccine Resources](#) for additional job aids.

COVID-19 Therapeutics Provider Warmline

The California COVID-19 Therapeutics Provider Warmline is available for healthcare professionals in California-based long-term care and skilled nursing facilities until June 30, 2024!



The National Clinician Consultation Center offers free and confidential consultation on COVID-19 testing and treatment. Healthcare professionals in California working in a long-term care or skilled nursing facility of any experience level can speak with our clinician or pharmacist.

No Protected Health Information (PHI) will be collected -- only basic provider contact and facility information.

Call 1-866-268-4322 (1-866-COVID-CA) or submit an [online request form](#). Hours: Monday through Friday, 9AM – 5PM. All voicemail messages will be returned on the next business day.

CDPH Office of Communications: Mpox Toolkit

Toolkit Spotlight: Mpox Communications Tools for Local Health Jurisdictions and Community-Based Organizations

California is seeing an increase in the number of mpox cases reported across the state. To reinforce awareness and prevention, CDPH recently issued a [health advisory for healthcare providers](#) about how to recognize and treat mpox.

Visit the [CDPH Mpox Campaign Toolkit for Local Health Jurisdictions and Community-Based Organizations](#) to share messages about mpox awareness and prevention. The toolkit features customizable digital ads and print materials in **English** and **Spanish**.

Additional resources:

- [CDPH Mpox Webpage](#)
- [Mpox Communications Toolkit](#)




CDPH Office of Communications: Pneumonia

Suggested Message: Pneumonia Awareness

Pneumonia is an infection of the lungs caused by viruses, bacteria, or other germs. Pneumonia can cause severe illness in people of all ages. Some types of pneumonia can be prevented with vaccines.

As World Pneumonia Day was November 12, 2023, share [messages on social media](#) raising awareness about pneumonia.

Learn more about [pneumonia and prevention with vaccines](#).



COVID-19 Vaccine Administration Data

Sarah Stich, CDPH


COVID-19 Vaccine Administration Summary

as of November 15, 2023

93,334,025

Total Doses Administered:


Daily Doses Administered: **Statewide**



3,424,611

Total Up-to-Date* Recipients:

Percent of Population Who Are Up-to-Date



*Has received a dose of the Updated 2023-2024 vaccine

Trends in COVID-19 Vaccine Administration

as of November 15, 2023

Most Recent Eligibility Groups

Updated 2023-2024 COVID-19 vaccine for 6 months and older


FDA NEWS RELEASE

FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

[f Share](#) [t Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

For Immediate Release: September 11, 2023

Doses Administered by Age Group, Past 4 Weeks



Up-to-Date Status by Healthy Places Index (HPI)

as of November 15, 2023


HPI Quartile: % of Population by Vaccine Status:

Up To Date | Received Bivalent but Not Up to Date | Any Shot but Not Up To Date | No Shots

COVID-19 Vaccine

Highest uptake in Healthy Places Index 3 & 4

Over half of those in each equity quartile have received a shot but are not Up-to-Date




COVID-19 Vaccine Data Up-to-Date of 65+ by County

as of November 15, 2023

By geography and age:

Uptake varies geographically

Ranges from **3.4%-43.3%** of county's 65+ population



Updated 2023-2024 COVID-19 Doses by Provider

as of November 15, 2023

Number of Updated 2023-2024 Dose Providers vs Bivalent Dose Providers


By provider:

4,648

Total Updated 2023-2024 Dose Providers
Reported

69% of previous Bivalent
vaccine Providers

+5% pt increase from last week



Updated 2023-2024 COVID-19 Vaccine Doses by Provider

as of November 15, 2023


By dose and provider:

Administration type varies by vaccine

53% of Bivalent doses

VS

56% of Updated 2023-2204 doses administered by pharmacies



COVID-19 Vaccine Data Summary

as of November 15, 2023

Key Metrics

93.3 million doses administered

| **+340K** doses administered

8.6% Statewide who are Up-to-Date

| **3.4 million** Up-to-Date recipients

3% HPI Q1 who are Up-to-Date

| **311 thousand** HPI Q1 Up-to-date recipients

System Notes

- Public dashboard Up-to-Date status now **includes** the Updated 2023-2024 guidelines
 - Public dashboard updated monthly – LHJ Dashboard updated daily
- Email cdphvaccinatedatateam@cdph.ca.gov for questions and comments

Clinical Guidance

Tarek Salih, MD, CDPH

Mpox in California

- Cases currently on the rise (average of 20 per week over last 4 weeks), up from <1 case per week over the summer.
- ~40% of cases were previously vaccinated (1 or 2 doses).
- Only 30% of at-risk population living with human immunodeficiency virus (HIV) have received even 1 dose of JYNNEOS.
- 34.8% (66,540 people) who received a 1st dose of JYNNEOS still need a 2nd dose to complete the series.

ACIP Meeting 10/25/23 Mpox Update

ACIP recommends vaccination* with the 2-dose[†] JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox[§]?

*Interim recommendation to be revisited in 2-3 years


[†] Dose 2 administered 28 days after dose 1

[§] Persons at risk:

- Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
 - A new diagnosis of ≥ 1 sexually transmitted disease
 - More than one sex partner
 - Sex at a commercial sex venue
 - Sex in association with a large public event in a geographic area where mpox transmission is occurring
- Sexual partners of persons with the risks described in above
- Persons who anticipate experiencing any of the above

ACIP Meeting 10/25/23 Mpox Update: VFC*

- JYNNEOS is included in Vaccines for Children (VFC) program for people aged 18 years
 - Current ACIP recommendation for people 18y/o and over
 - Future ACIP recommendation to include children under 18y/o → will become available to under 18y/o at that time
- Ongoing clinical trial: Safety and immunogenicity of JYNNEOS in persons aged 12 years – 17 years



*Jynneos will not be available through the VFC program immediately following the passage of this resolution because they are not yet commercially available.


ACIP Meeting 10/25/23 Mpox Update: Coadministration

- There is no required minimum interval between receiving any COVID-19 vaccine and JYNNEOS vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first.
- People, particularly adolescent and young adult males, who are recommended to receive both vaccines might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines and the hypothetical risk for myocarditis and pericarditis after JYNNEOS vaccine. However, if a patient's risk for mpox or severe disease due to COVID-19 is increased, administration of JYNNEOS and COVID-19 vaccines should not be delayed.

Pharmacy

Edward Salaguinto, PharmD, RPh, CDPH

Find Bridge Access Program (BAP) Pharmacies



- ❖ Actively working with our federal partners on LTC facility needs for staff members
- ❖ Identified all pharmacies that either have their primary or secondary focus on LTCs
- ❖ Some of the pharmacies on our list are Retail and LTC pharmacies and others are considered 'closed door' and only support facilities without offering any retail operations.

To register, visit:
www.joinetrueenorth.com



The Bridge Access Program is funded by the U.S. Department of Health and Human Services and the Center for Disease Control and Prevention.

All pharmacy applications are subject to approval by HHS.

Bridge Access Program

eTrueNorth, in partnership with HHS,* is helping expand free COVID-19 vaccine access in communities across the U.S.

Through the Bridge Access Program, pharmacies enrolled with eTrueNorth can receive reimbursement for administering no-cost COVID-19 vaccines to uninsured and underinsured adults.



By encouraging enrollment, you can:




Help pharmacies **expand access to the underserved** members of your community.



Streamline **access to reimbursement** for vaccinations administered to the **uninsured** population.



Support more **robust IIS reporting**.



Sunseting

U.S. Government COVID-19 Therapeutics Distribution Program

| Section | Description of Change | Publication Date |
|--|---|------------------|
| Winter COVID-19 Treatments Transition | Updated details regarding Lagevrio ordering for federal entities during commercial transition. | 11/14/2023 |
| Ordering and Distribution Timelines | Updated description of Pfizer PAP and clarified out of cycle request and ordering process. | 11/14/2023 |
| Program for Uninsured and Underinsured Individuals | Web link included for Paxlovid Co-Pay Savings Program ↗ . | 11/14/2023 |
| Related Resource: COVID-19 Therapeutics Commercialization: Frequently Asked Questions | FAQ published to answer questions related to access for uninsured and underinsured individuals, patient assistance programs, the Test to Treat program, and other common questions related to commercialization of COVID-19 therapeutics. | 11/14/2023 |

Programs for Uninsured and Underinsured Individuals

| Product | Programs | Description and Additional Information |
|----------|---|--|
| Lagevrio | Patient Assistance Program | Information available November 17, 2023 Tel: 800-727-5400 |
| | Bulk Replacement Program | Tel: 888-727-8180 Website: merckhelps.com |
| Paxlovid | Available November 1, 2023: | Information available November 1, 2023 |
| | Co-Pay Savings Program | Co-Pay Savings Program will be available for eligible commercially insured patients |
| Paxlovid | Available December 1, 2023: | Information available December 1, 2023 |
| | Patient Assistance Program using USG supply | <p>Website: For Patients https://www.paxlovid.com/ Tel: 1-877-219-7225 (1-877-C19-PACK)</p> <p>Through December 31, 2024: Anyone uninsured or covered by federal programs, such as Medicare or Medicaid, can receive USG-procured, NDA-labeled Paxlovid at no cost through the USG PAP operated by Pfizer. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee. For retail pharmacies that would like to learn more about participating in the U.S. Government PAP, please contact the program vendor at PharmacyNetworkContract102101@assistrx.com.</p> <p>Starting January 1, 2025: Eligible uninsured and underinsured patients can receive USG procured, NDA-labeled Paxlovid at no cost. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee.</p> |



U.S. Department of Health and Human Services (HHS) COVID-19 Therapeutics Transition to Commercial Distribution FAQs

COVID-19 Therapeutics Transition to Commercial Distribution: Frequently Asked Questions

This resource provides answers to common questions related to access to COVID therapeutics, patient assistance programs, the Test to Treat program, and more.

[Read the FAQs](#)

Vaccine Management

Josh Pocus, My Turn, and Claudia Aguiluz, myCAvax

What's Next in My Turn? – Release 45 (1 of 2)



New updates for Patients will launch on
Monday, November 20, 2023!


Release Highlights



Patients will be able to view:

- ✓ New multi-select fields on the 'Patient information' page on selecting either the 'Asian' or 'Native Hawaiian or Other Pacific Islander' checkbox for the 'What is the patient's race or nationality?' (Select all that apply)' question
- ✓ The clinic's phone number on the clinic card on the 'Select a location' page
- ✓ Updated step numbers next to each step and a description below the 'Select a vaccine brand' field on the 'Select date & time' page
- ✓ Updated text throughout site to include "If you can't find a clinic that offers the vaccine you need, contact your healthcare provider or [local health department](#). You can also search for clinics on [Vaccines.gov](#) or use the [Mpox Vaccine Locator](#)."
- ✓ An updated minor consent message under the 'What to bring to appointment' header on the Confirmation page
- ✓ The 'COVID-19 doses by age' chart as a web page instead of a pop-up window
- ✓ An updated description on the 'Does the patient have health insurance?' question on the 'Let's get started' page

My Turn Public



What's Next in My Turn? – Release 45 (2 of 2)



New updates for Clinic Managers and Vaccine Administrators will launch on **Monday, November 20, 2023!**

Release Highlights



Clinic Managers and Vaccine Administrators will be able to view:

- ✓ New fields that show up on the 'Patient Background' section asking to specify the race when selecting 'Asian' or 'Native Hawaiian or Other Pacific Islander' from the 'Please select your race or nationality' dropdown on the Walk-in, IIS, and VA flows
- ✓ The new 'Specify "Asian",' 'Specify "Pacific Islander",' and 'Race not listed' columns / fields on the CSV / Inline Bulk Upload flow based on the race selected
- ✓ The 'An emancipated minor at least 16 years of age' validation on the 'Minor Consent' section while creating COVID-19 and flu appointments on the Walk-in, IIS, and VA flows, only for patients of age 16–17 years
- ✓ The 'Emancipated Minor' option on the 'Consent Type' dropdown while creating COVID-19 and flu appointments on the Inline Bulk Upload flow, only for patients aged 16–17 years
- ✓ The 'Emancipated Minor' validation for patients aged 12–17 when creating mpox appointments on the Inline Bulk Upload flow
- ✓ The new 'Vaccinator Title' field in the 'Administration Information' section of an appointment and the 'Vaccinator Title' dropdown on the CSV and Bulk Upload flows

Clinic Managers will be able to view:

- ✓ The new 'Vaccinator Title' dropdown on the 'Vaccine Administration' section on the VA and IIS flows
- ✓ The new 'Vaccinator Title' dropdown on a Contact
- ✓ The 'IIS Enabled' checkbox on the Clinic Manager contact automatically checked upon creation while creating a contact through the Digital Enrollment flow, Add User, and Bulk Upload User functionalities

Clinic Managers will no longer be able to view:

- ✓ The 'Username' column on the CSV file while creating a user via the Bulk Upload User functionality

Vaccine Administrators will be able to view:

- ✓ The 'Welcome to My Turn Clinic' image under the 'Home' tab on the My Turn Clinic home page

My Turn Roadmap



Nov–Dec 2023

- CAIR Quick Entry MVP
- Public updates to include the phone number on clinic cards
- Public UI updates to the 'Select date & time' page
- Public updates to remove the VA chat bubble from the Public portal
- Public updates to add new race expansion values for the Asian and Native Hawaiian races

Jan–Mar 2024

- CAIR Quick Entry Enhancements
 - Pre-filled rows
- School Vaccinations
 - Clinic vaccine support for the Vaccines for Children (VFC) program
 - Public school scheduling support for in-school vaccinations

Mar–May 2024

- School Vaccinations
 - Clinic vaccine support for the VFC program
 - Public school scheduling support for in-school vaccinations

Jun–July 2024

- Outbreak Vaccine Support
 - Vaccines for Adults (VFA) and VFC Outbreak vaccine support

Regenerate Clinic-Specific Links



Clinic Managers, if you have clinic-specific links, regenerate and reshare as soon as possible. All existing links will not work properly.



Generate clinic link

This form will create a link to the My Turn public scheduling portal, which will allow patients to schedule directly with your clinic. This link and QR code will stay active until your clinic closes or you deactivate it. Your clinic QR code will be available after you press save.

Landing Page ⓘ

Scheduling

Language


English

[Cancel](#) [Save](#)

Increase in Mpox Demand: Steps to Increase Clinic Visibility

Due to the increase in the mpox vaccination demand, Clinic Managers and Vaccine Administrators are encouraged to follow the steps below to increase clinic visibility.

My Turn Public Google Analytics Oct 2023



- 
- 1 If not already, enroll your mpox clinic in [My Turn](#)
 - 2 At your clinic, update appointment availability, vaccine offered, and clinic tags
 - 3 If not enrolled in My Turn, contact Dr. Caterina Liu and request to appear on the [Mpox Locator](#) (happens automatically if enrolled in My Turn)

My Turn COVID-19 Testing Locations (1 of 3)



Note to providers: You can list a new location or update your current location by submitting a [Testing site information form](#).
Questions? Email us at testinglocations@cdph.ca.gov.

On the 'Find a testing site' page on the My Turn Public portal, providers may create, update, or delete testing sites they manage using the new hyperlink at the bottom of the page.



My Turn COVID-19 Testing Locations (2 of 3)



To update or delete a testing site location, input the location's Testing Site ID (TS-ID) on the 'Testing site information' page.



Testing site information

To list, update, or delete a testing site location on My Turn, simply complete and submit the following form.

What would you like to do?

☐ List a new location ☒ Update a location ☐ Delete a location

Please enter ID: ?

TS-127

Requester's email address

Please enter your business or public email only (no personal emails).

janedoe@clinic.com

Test site name

ABC Clinic

My Turn COVID-19 Testing Locations (3 of 3)



After CDPH reviews the testing site creation / update request, providers will receive an email approving or denying the request. If denied, the email will provide the reason and a link to resubmit.



Your request has been approved - Request ID [R-002] 😊 ↩ ⏪ ⏩

CM ☐ **CDPH My Turn Form <myturn.ca.gov>** Tuesday, November 01, 2022 at 10:00 AM

To: ☐ CDPH Testing Locations

This message is from an EXTERNAL SENDER - be CAUTIOUS, particularly with links and attachments.

This email contains a reference to coronavirus or COVID-19. Please be aware of coronavirus-themed active phishing campaigns, and use extra vigilance when responding or clicking.



Congratulations! Your request [R-002] for testing site [TS-620] has been approved and will be live on My Turn within 3 business days.

Please remember to review and update your testing site information every 90 days. These reviews help ensure our records are correct and the public receives the most up-to-date information about your testing site.

Note: Your unique testing site ID appears on the bottom right of your site's card on the [Find a testing site page](#).



Your request has been declined - Request ID [R-002] 😊 ↩ ⏪ ⏩

CM ☐ **CDPH My Turn Form <myturn.ca.gov>** Tuesday, November 01, 2022 at 10:00 AM

To: ☐ CDPH Testing Locations

This message is from an EXTERNAL SENDER - be CAUTIOUS, particularly with links and attachments.

This email contains a reference to coronavirus or COVID-19. Please be aware of coronavirus-themed active phishing campaigns, and use extra vigilance when responding or clicking.



We're sorry, your request [R-002] for testing site [TS-620] has been declined for one of the following reasons:

- Received a request for removal
- Duplicate site
- Inactive site
- Site only offers take home test
- Site is only for specific patients

Please review and correct the information you provided for this listing and submit a new [Testing site information form](#).

Note: Each approved testing site on My Turn is assigned a TS number. This unique ID appears on the bottom right of your site's card on the [Find a testing site page](#).

Bridge Access Program (BAP): Vaccine Allocations Cadence Update



As of **October 25, 2023**, allocations of BAP COVID-19 vaccine products will be refreshed on a biweekly cadence. CDPH anticipates allocations being received mid-week and will distribute inventory to the LHDs by the following business day.



The most recent allocation refresh was on **Thursday, November 9, 2023**.

BAP / Vaccines for Adults (VFA) Eligibility Overlap

Vaccine and Clinic Eligibility Guidelines by Funding Source

For Health Departments and CDPH Approved Health Department Authorized Sites (Effective 10/01/2023 through 9/30/2024)



| Program |  VFC Vaccines for Children Program |  BAP Bridge Access Program | 317 Local Health Departments ^{1,5} | VFA Vaccines for Adults Program | SGF State General Funds ² |
|----------------------------|--|--|--|---|--|
| Funding | VFC-Federal entitlement program for eligible children. Funds are used to pay for vaccines recommended by ACIP and approved into the VFC program. | BAP-Limited federal funds (Section 317) for eligible adult populations to maintain access to COVID-19 vaccines through existing public health infrastructure. | 317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and support limited vaccine supply for outbreak activities via Public Health Departments. | 317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and included in the VFA Program. | Limited state funds for the purchase of vaccines to prevent respiratory illness. |
| Age and Eligibility | Children Birth–18 years: <ul style="list-style-type: none"> • Medi-Cal/CHDP eligible • Uninsured (no health insurance) • American Indian or Alaskan Native • Underinsured: health insurance does not cover vaccines (ONLY if the LHD has a FQHC or RHC designation). | Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured (no health insurance) • Underinsured (vaccines are not covered by insurance or requires a co-payment) <p>(Adults with Medicare part B and D are considered insured and not eligible to receive 317 BAP vaccines.)</p> | Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance) • Insured exceptions-Adults part of outbreak control, post-exposure prophylaxis, or disaster relief efforts as approved by CDPH & LHDs. • Household contacts or sexual contacts of HBsAg+ pregnant woman | Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance) | All ages: <ul style="list-style-type: none"> • No restrictions |
| Clinic Type | <ul style="list-style-type: none"> • Federally Qualified Health Center (FQHC), Rural Health Center (RHC), and State-licensed • Community Health Centers • Health Department and CDPH Approved Health Department Authorized Sites • Juvenile halls/youth correctional facilities • Private providers, School-based clinic, Hospitals, Pharmacies (pilot program) | <ul style="list-style-type: none"> • Health Department Clinics • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Tribal Clinics • Indian Health Services • Limited sites designated by Local Health Department as BAP Provider | <ul style="list-style-type: none"> • Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Juvenile halls/youth correctional facilities (for 19-25 years of age) | <ul style="list-style-type: none"> • VFC enrolled Federally Qualified Health Center (FQHC), Rural Health Center (RHC) | <ul style="list-style-type: none"> • State-licensed Community Health Centers • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Private provider • School-based clinic |

California Department of Public Health, Immunization Branch


IMM-1142 (10/17/23) Page 1

All uninsured / underinsured adults, 19 years and older are eligible for BAP and VFA vaccines.


Adults with Medi-Cal, Medicare Part B, or Medicare Part D are not eligible for BAP vaccines.

However, adults with Medicare Part B alone or Medicare Part D alone are eligible for certain VFA vaccines. Refer to [VFA Eligibility Based on Insurance Status](#) for more details.

BAP Insurance Flow



Vaccines for Children (VFC) Insurance Flow



Refresher: Ordering Vaccine Product



myCAVax COVID-19 Vaccine Management System

Home My Programs My Turn Vaccine Order Vaccine Inventory Reports More

BAP COVID-19 - Order Request
Step 1 - Select Account and Product

Need help? Review the job aid(s) for [placing vaccine order requests](#), [COVID-19 product guide](#), [shipping cadence](#) and [managing storage units](#).

Select Location, Provide Inventory and Doses Administered for Vaccine you Intend to Order

- Select the location account.
- Review your Reported Inventory that is automatically pulled from the latest data in VaccineFinder every afternoon at 2pm PST.
- If the VaccineFinder inventory is incorrect, update your inventory on the [VaccineFinder](#) website per CDC guidelines.
- Enter your On-Hand Inventory and Doses Administered only for the vaccine(s) you intend to order.

*Account
Rashmal's Unicorn Island

myCAVax COVID-19 Vaccine Management System

Home My Programs My Turn Vaccine Order Vaccine Inventory Reports More

State General Fund - Vaccine Order Request
Step 1 - Select Account and Product

To change the program selected, navigate back to the [Vaccine Orders page](#).

Select Location, Provide Inventory and Doses Administered for Vaccine you Intend to Order

- Select the location account.
- Enter your On-Hand Inventory and Doses Administered only for the vaccine(s) you intend to order.

*Account
Rashmal's Unicorn Island

Only enter values for products you want to order, otherwise leave fields blank.

| Vaccine product | Quantity | Lot number | Expiration Date | Qty since last order | Doses requested |
|--|----------|------------|-----------------|----------------------|-----------------|
| PED Fluax SDS (6 mos - 18 yrs) - 10/box - 2023-2024 SGF | | | | | 0 |
| Unavailable for Ordering | | | | | |

Providers can place vaccine order requests for BAP COVID-19 and State General Fund (SGF) vaccines from the 'COVID-19 - Order Request' and 'State General Fund - Vaccine Order Request' pages, respectively. Providers must have an active program location to order vaccines.

Thanksgiving BAP Holiday Shipping Cadence

Thanksgiving Holiday Ordering & Distribution Cadence Calendar

California BAP COVID-19 Vaccination Program(Providers/LHDs)

| Week 1 | Monday | Tuesday | Wednesday | Thursday | Friday |
|--------|--|---------|-----------------------|---------------------------------------|--------|
| | November 20 | 21 | 22 | 23 | 24 |
| | Provider Order (submit by 5PM) | | LHD Approval by 12PM | Holiday Holds – No Vaccine Deliveries | |
| | | | CDPH Transmits to CDC | | |
| | Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer** (orders processed 11/15/23) | | | | |
| | | | | | |

| Week 2 | Monday | Tuesday | Wednesday | Thursday | Friday |
|--------|--|---------|-----------------------|----------|-------------|
| | 27 | 28 | 29 | 30 | December 01 |
| | Provider Order (submit by 5PM) | | LHD Approval by 12PM | | |
| | | | CDPH Transmits to CDC | | |
| | Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer | | | | |
| | | | | | |



- Delivery windows are dependent on provider's days/hours of operation. Shipments will be sent the following week of order approval and processing.[** Adjusted Delivery date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

Thanksgiving SGF Holiday Shipping Cadence

November Holiday Ordering & Distribution Cadence Calendar




California SGF Flu Vaccination Program(Providers/LHDs)

| Monday | Tuesday | Wednesday | Thursday | Friday |
|---|--|--------------------------------------|---|--|
| November 06 | 07 LHD Approval by 12PM CDPH Transmits to CDC | 08 | 09 Flu Vaccine Delivery – McKesson Direct Ship** | 10 Holiday Holds – No Vaccine Deliveries |
| 13 Provider Order (Submit by 12PM)** | 14 LHD Approval by 12PM CDPH Transmits to CDC | 15 Provider Order (Submit by 5PM) | 16 Flu Vaccine Delivery – McKesson Direct Ship | 17 LHD Approval by 12PM CDPH Transmits to CDC Provider Order (Submit by 5PM) |
| 20 | 21 LHD Approval by 12PM CDPH Transmits to CDC Flu Vaccine Delivery – McKesson Direct Ship | 22 | 23 Holiday Holds – No Vaccine Deliveries | 24 Holiday Holds – No Vaccine Deliveries |
| 27 Provider Order (Submit by 12PM)** | 28 LHD Approval by 12PM CDPH Transmits to CDC Flu Vaccine Delivery – McKesson Direct Ship** | 29 | 30 | December 01 LHD Approval by 12PM CDPH Transmits to CDC Provider Order (Submit by 5PM) |



- Delivery windows are dependent on provider's days/hours of operation. [** Adjusted Delivery or order submission date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

Slide Icon Key

| Icon | Meaning |
|--|--|
|  | This is to label slides that are referencing upcoming or existing functionality and how to use it in the system. |
|  | This is to label slides that include important system reminders. |
|  | This is to label slides that include tips and best practices to improve your system experience. |

My Turn – Known Issues and Workarounds



Known Issues

Eligibility and Scheduling Clinic Links

- ✓ Both the Eligibility and Scheduling clinic links are directing Clinic Managers to the My Turn home page when they are trying to make an appointment.



Workaround / Next Steps

- ✓ Fixed: **November 9, 2023**
- ✓ Note that existing clinic links will not work – new clinic links will need to be generated for patients to be directly sent to the clinic when booking appointments.

myCAvax – Known Issues and Workarounds



Known Issues

'Physician's Assistant' License Type on SGF Enrollment Leading to Endless Spinner

- ✓ For LHD users still completing their SGF enrollment, if you add a Provider of Record with a license type of 'Physician's Assistant,' you will be met with an endless spinner when trying to complete your enrollment.

Fluarix Shipment Not Showing the Correct Product

- ✓ It has been reported that for some orders of ADU Fluarix, the shipment is showing as PED Fluarix and vice versa. In addition to fixing the logic, we have also cleaned up previously affected shipments.



Workaround / Next Steps

- ✓ Fixed: **November 2, 2023**

- ✓ Fixed: **November 9, 2023**

Vaccines for Children (VFC) Updates

Claudia Aguiluz, CDPH

Nirsevimab (Beyfortus™) Vaccine Supply

- Allocations from CDC continue to be limited and will last for the rest of the 2023-2024 RSV season.
- We have received a maximum number of doses we can expect for the remainder of the season. Doses have been incrementally allocated, every 2-3 weeks
- An additional allocation for the 100mg Beyfortus™ formulation is expected next week.

Nirsevimab (Beyfortus™) Ordering

- Ordering is currently limited by formulation, provider type, and based on historical Hep B orders for hospitals, and pneumococcal conjugate vaccines (PCV), for all other provider types.
- 50mg
 - Now available for ordering for all provider types.
 - Providers with lower historical usage of sentinel vaccines are unable to submit a request for doses at this time, and their order line for nirsevimab will be grayed out.
- 100mg
 - Ordering is only available to hospitals, Tribal Health Clinics, selected Federally Qualified Health Centers (FQHCs)/Rural Health Centers (RHCs) and Public Health Department Clinics.
 - With additional allocations expected next week, ordering will be opened to all provider types.

COVID-19 Vaccine Ordering

- All VFC providers are required to order and offer ACIP recommended vaccines, which includes COVID vaccines, to their patient population.
- The VFC Program's goal is to reduce barriers to vaccination, and ensure children receive all the indicated vaccine doses within their medical home.
- Please ensure your practice continues to order and administer COVID vaccine to meet the needs of all VFC-eligible patients seen at your practice.
- Any vaccine spoiled/wasted due to ordering and not administering the minimum amounts needed for your total VFC-eligible patient population will not be considered a negligent vaccine loss.
- If you need any additional information or assistance in the implementation of this vaccine, please email us at MyVFCVaccines@cdph.ca.gov

Upcoming Vaccines

RSV

- **Abrysvo** (Pfizer) – maternal RSV vaccine during weeks 32 – 36 of pregnancy
- Expected to be on the CDC contracts, further information on timeline and pricing is forthcoming

• MPOX VACCINE

- On 10/25/23, ACIP recommended vaccination with the 2-dose JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox, and added to VFC through a VFC resolution
- Mpox vaccines will not be available through the VFC program immediately following the passage of this resolution because they are not yet commercially available

• MenABCWY Vaccine

- PENBRAYA (Pfizer), also voted on 10.25.23 for inclusion in the VFC Program
- May be used when both MenACWY and MenB are indicated at the same visit
- Will be made available through VFC once a CDC contract and supply are available

2024 Immunization Schedules Now LIVE



- The [2024 ACIP Recommended Immunization Schedules](#) were posted online yesterday!
- Earlier availability of the 2024 Immunization Schedules is part of CDC's efforts to better support immunization professionals and improve timely implementation of new recommendations.
- Schedules summarize final recommendations that were previously adopted and made official by the CDC director.
- The new schedules include October 2023 recommendations for use of mpox and pentavalent meningococcal vaccine. In addition, they include updated recommendations for COVID-19, RSV, and Influenza vaccines.

VFC Holiday Shipping Schedule

- There will be limited shipping the weeks of November 20, 2023, and December 18, 2023.
- The VFC Program's National Vaccine Distributor, McKesson Specialty, Pfizer (shipments of COVID-19 vaccine), and Merck (shipments of varicella-containing vaccine) will not ship routine vaccines during the following dates:
 - Wednesday, November 22, 2023, through Friday, November 24, 2023
 - Wednesday, December 20, 2023, through Friday, December 29, 2023

IMPORTANT: If your site plans to close temporarily for the holidays, please wait to submit your vaccine order upon your return. Update your shipping hours to reflect your closure to prevent any shipping incidents that could lead to vaccine waste.

Key Order Cutoff Dates

| Order By* | Receive By |
|----------------------|----------------------|
| Tuesday, November 14 | Tuesday, November 21 |
| Tuesday, December 12 | Tuesday, December 19 |

*Please note, orders must be approved by the VFC Program by the above "Order By" date

COVID-19 Vaccines and Low-Dead Volume Syringes



Kelley Leung, RN, CDPH

Low-Dead Volume (LDV) Syringes

Previous Guidance

Withdrawing doses of vaccine from the vial

After mixing, use low dead-volume syringes and/or needles to withdraw doses of vaccine. If sufficient quantities of low-dead volume syringes are not available to withdraw all doses, use a combination of low dead-volume syringes and non low-dead volume syringes.



Current Guidance:

- Most products are now distributed as single dose vials.
- LDV syringes no longer required for COVID-19 Vaccine Administration.
- Multi-dose vials (Pfizer 6mos-4yrs and Novavax) do not require the use of LDV for vaccine administration.
- Please ensure that your site has the most updated [product information](#) for the vaccine products being offered at your location.

Resources and Q&A

Leslie Amani and CDPH SMEs



Holidays and Webinar Cancellations

Thursday, November 23: **Happy Thanksgiving!** 

Friday, November 24: There will be **no** Friday provider webinar the day after Thanksgiving.

Please note that the Provider Call Center will be closed on these same dates.

EZIZ.ORG

(Easy Immunization)

Please bookmark
<https://eziz.org/>
for immunization
updates, resources,
and guidance

The screenshot displays the EZIZ.ORG website layout. On the left is a green sidebar with navigation links: Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, Training & Webinars, Clinic Resources, and Patient Resources. Below these is a 'Contact VFC' section with phone, hours, and email information, followed by links for VFC Field Representatives, finding providers, signing up for emails, and frequently asked questions.

The main content area is titled 'California's Vaccine Programs' and features four boxes for VFC (Vaccines for Children), VFA (Vaccines for Adults), BAP (Bridge Access Program), and 317 (Local Health Departments). Below this is a table with two columns: 'Ordering & Vaccine Management' (listing MyVFCvaccines and MyCAvax) and 'Storage Requirements' (listing Vaccine Storage Units and Digital Data Loggers).

An 'Alerts!' section follows, featuring a '2023-24 COVID-19 Vaccine' alert with links for provider and patient resources, and vaccine ordering information. Below this is a section to 'Protect your patients against RSV!' with links to RSV FAQs, RSV resources for providers and patients, and a Nirsevimab guide.

A 'Thanksgiving Holiday Ordering & Distribution Cadence Calendar' section lists links for the California Bridge Access COVID-19 Vaccination Program, the California SGF Flu Vaccination Program, and the California Mpox Vaccination Program.

The 'New/Updated Materials' section is circled in orange and lists: 'Accessing COVID-19 Vaccine Infographics for Patients' (with options for English and Spanish for both Vaccines for Children and Bridge Access Program), 'Fall-Winter 2023 Immunizations Infographic', 'Sticker Templates to identify program vaccine' (for VFC, VFA, BAP, and 317), and 'Immunization Schedule Using Combination Vaccines'.

On the right side, the 'Hot Topics' section is highlighted with an orange circle and includes 'Weekly CDPH Immunization Updates for Providers' and links to 'Immunization Registry Requirements' and 'COVID-19 Vaccine Resources'. Below this is a 'Popular Resources' section with links for patients and staff, flu, mpox, pertussis, schedules, fact sheets, and pharmacies. At the bottom right is a 'CDPH Applications' section with links for My Turn, CAIR, My DVR, and CAIR-ME.

Provider Operations Manual

California Bridge Access Program


Special Note for Providers

You played a critical role in helping to end the COVID-19 pandemic.

For patients, you are one of the most trusted sources of information when it comes to vaccines. Patients may have questions and concerns about COVID-19 vaccines. You can help them understand the importance of vaccination, provide your strong recommendation, and build confidence in vaccines.

Strong vaccine confidence leads to more people getting vaccinated, which leads to fewer COVID-19 illnesses, hospitalizations, and deaths.

Thank you for the efforts you and your practice staff are making to keep California healthy.





California Bridge Access Program

Provider Operations Manual

no-cost
COVID-19 vaccines

thank
you

for uninsured &
underinsured adults



California
Bridge Access
Program

[Click to Navigate](#)
Table of Contents

[Startup Guide](#)

[Appendices](#)
Important contacts

[Infrequent Tasks](#)
Introduce new vaccines, change staff or contacts, set up new storage unit, and data logger

1

Ordering Vaccines

About vaccine orders
Vaccine products
Submitting vaccine order requests
Minimizing shipment delays
When to expect vaccines



2

Receiving & Storing Vaccine Shipments


About receiving shipments
Moderna
Novavax
Pfizer-BioNTech
Reporting shipment incidents



3

Routine Tasks & Reporting

Recurring tasks & frequency
Reporting requirements
Reporting temperature excursions
Expiration & beyond-use dates
Wastage & missed opportunities
Reporting & return of nonviable doses
Transferring vaccines
Transferring vaccine



4

Managing Vaccine Inventory

Inventory management checklist
Monitoring temperatures
Reporting temperature excursions
Expiration & beyond-use dates
Wastage & missed opportunities
Reporting & return of nonviable doses
Transferring vaccines
Transferring vaccine



5

Patient Visit

Patient visit checklist
Eligibility
Screening & Documentation
How to Screen & Document Eligibility
Vaccine preparation & administration
Responding to administration errors
Billing & Reimbursement



COVID-19 Vaccine Provider FAQs

Answers to provider COVID-19 vaccine questions updated November 16, 2023



Q: Is there required training for Bridge Access Program (BAP) providers?

A: Any staff who store, handle, or administer COVID-19 vaccines must complete [COVID-19 Vaccine Product Training](#), only for products your location will order, prior to receiving vaccine shipments.

Staff who conduct eligibility screening should be trained using [Eligibility Based on Insurance Status](#) and [Eligibility Screening & Documentation Requirements](#).



Q: Are providers required to provide Emergency Use Authorization (EUA) fact sheets to vaccine recipients or their caregivers?

A: Yes, currently providers are required by law to provide EUA fact sheets to vaccine recipients or their caregivers for all uses of [Novavax](#), and when [Moderna](#) or [Pfizer](#) vaccines are given to children 6 months through 11 years of age.

For recipients who are 12 years or older receiving Pfizer or Moderna vaccine, a provider should use the [COVID-19 Vaccine Information Statement](#) (VIS).

COVID-19 Vaccine FAQs v.135_11.16.23 1

COVID-19 Vaccine FAQs

For providers administering COVID-19 vaccine.
Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

| | |
|----------------------------------|----|
| New and Updated FAQs..... | 2 |
| COVID-19 Vaccine Access..... | 3 |
| Bridge Access Program (BAP)..... | 5 |
| Vaccine Administration..... | 8 |
| Vaccine Storage & Handling..... | 10 |
| Reporting..... | 11 |
| Communication Resources | 13 |

Vaccine Support


Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



COVID-19 Therapeutics Resources

Type of Support


Description

Updated 10.6.23



Clinical Guidance

For general Therapeutics questions, please email: COVIDRxProviders@cdph.ca.gov



General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)


[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



[LHJ Therapeutics SharePoint](#)

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email JEOCuser54@cdph.ca.gov)

- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPoP Account Verification & Reporting](#) information



Questions

For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov

For ordering, program inquiries, signing up new HPOP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov


CDPH Provider Webinars and Trainings

Week of November 20, 2023

| | Monday 11/20 | Tuesday 11/21 | Wednesday 11/22 | Thursday 11/23 | Friday 11/24 |
|----------------------------|---|---------------|--|--|---|
| Live Webinars and Training | | | | <i>Holiday</i> | <i>Holiday</i> |
| View On Demand | <ul style="list-style-type: none"> CDPH Weekly Provider Archived Webinars and Slides COVID-19 Crucial Conversations Archived Webinars and Slides AIM Vaccine Confidence Toolkit Webinar Series | | <ul style="list-style-type: none"> Introduction to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires myCAVax Login) myCAVax Release Notes for LHD and CDPH Users (Requires myCAVax Login) | | <ul style="list-style-type: none"> Moderna COVID-19 Vaccine Resources for Providers CDC COVID-19 Vaccination Clinical & Professional Resources Novavax COVID-19 Vaccine Information Pfizer COVID-19 Vaccine (COMIRNATY) Information |
| Help | <p>Help Desk</p> <p>*CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov</p> <p>My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov</p> <p>myCAVax: Help Desk Email: mycavax.hd@cdph.ca.gov Mpox: Email: stdcb@cdph.ca.gov</p> <p>COVID-19 Treatments: Warmline for LTCF/SNF staff: 1-866-268-4322, M-F 8am-5pm, Test to Treat Help Form</p> | | | <p>Immunization Resources</p> <p>California's General Immunization Resources (eziz.org)</p> <p>RSV Immunization Resources Flu Vaccination Resources</p> <p>COVID-19 Vaccination Resources COVID-19 Treatments</p> <p>Mpox Vaccination Resources</p> | |

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be
dropped into, “Chat”



Upcoming Webinar Opportunities

CDPH Immunization Updates for Providers

Next session: Friday, December 1, 2023

9AM – 10:30AM

